Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Recruiting
Allergan
Phase 4
2011-05-02
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in
children 3 to less than 17 years old, who have overactive bladder due to a neurogenic
condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then
return to the clinic for a potential dose titration. At this time their dose may be adjusted
up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the
individual response and tolerability. The total treatment time is 14 weeks and total time on
the study is 16 weeks.
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Recruiting
Watson Pharmaceuticals
Phase 4
2011-05-02
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in
children 3 to less than 17 years old, who have overactive bladder due to a neurogenic
condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then
return to the clinic for a potential dose titration. At this time their dose may be adjusted
up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the
individual response and tolerability. The total treatment time is 14 weeks and total time on
the study is 16 weeks.
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
Completed
Astellas Scientific & Medical Affairs, Inc.
2015-01-05
A study to identify factors that are associated with improved effectiveness in pharmacologic
therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF
(Overactive Bladder Questionnaire Short Form)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
